FP3: A novel VEGF blocker with antiangiogenic effects in vitro and antitumour effects in vivo

Clinical and Translational Oncology

Volumn 13, Issue 12, 2011, Pages 878-884

  Jin, Ketao ^a,b   He, Kuifeng ^a   Teng, Fei ^c   Li, Guangliang ^a   Wang, Haohao ^a   Han, Na ^d   Xu, Zhenzhen ^d   Cao, Jiang ^a   Wu, Jianming ^a,e   Yu, Decao ^a,e   Teng, Lisong ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF TORONTO   (Canada)

^d ZHEJIANG UNIVERSITY   (China)

^e Chengdu Kanghong Biotechnology Inc   (China)

Author keywords

Angiogenesis; Antiangiogenic effect; Antitumour effect; FP3; Vascular endothelial growth factor (VEGF)

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; FP 3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOASSAY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; RAT; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; AORTA; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862907556     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0749-z     Document Type: Article

References (24)

1. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249-257
2. Rafii S, Lyden D, Benezra R et al (2002) Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2:826-835 (Pubitemid 37328901)
3. Shibuya M (2001) Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 26:25-35 (Pubitemid 32421949)
4. Giaccone G (2007) The potential of antiangiogenic therapy in non-small cell lung cancer. Clin Cancer Res 13:1961-1970 (Pubitemid 46649861)
5. Teng LS, Jin KT, He KF et al (2010) Advances in combination of antiangiogenic agents targeting VEGF-binding and conventional chemotherapy and radiation for cancer treatment. J Chin Med Assoc 73:281-288
6. Teng LS, Jin KT, He KF et al (2010) Clinical applications of VEGF-trap (afl ibercept) in cancer treatment. J Chin Med Assoc 73:449-456
7. Zhang M, Zhang J, Yan M et al (2008) Recombinant anti-vascular endothelial growth factor fusion protein effi ciently suppresses choroidal neovascularization in monkeys. Mol Vis 14:37-49
8. Zhang M, Yu D, Yang C et al (2009) The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization. Pharm Res 26:204-210
9. Kim JH, Kim JH, Yu YS et al (2008) Antiangiogenic effect of deguelin on choroidal neovascularization. J Pharmacol Exp Ther 324:643-647
10. Mountain DJ, Singh M, Singh K (2008) Downregulation of VEGF-D expression by interleukin-1beta in cardiac microvascular endothelial cells is mediated by MAPKs and PKCalpha/beta1. J Cell Physiol 215:337-343 (Pubitemid 351468945)
11. Nicosia RF, Ottinetti A (1990) Modulation of microvascular growth and morphogenesis by reconstituted basement membrane gel in threedimensional cultures of rat aorta: a comparative study of angiogenesis in matrigel, collagen, fi brin, and plasma clot. In Vitro Cell Dev Biol 26:119-128 (Pubitemid 20094385)
12. Staton CA, Stribbling SM, Tazzyman S et al (2004) Current methods for assaying angiogenesis in vitro and in vivo. Int J Exp Pathol 85:233-248 (Pubitemid 39319155)
13. Kim ES, Serur A, Huang J et al (2002) Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci U S A 99:11399-11404 (Pubitemid 34920937)
14. Dickson PV, Hamner JB, Sims TL et al (2007) Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 13:3942-3950 (Pubitemid 47037602)
15. Kamat AA, Merritt WM, Coffey D et al (2007) Clinical and biological signifi cance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 13:7487-7495
16. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342 (Pubitemid 38702844)
17. Reck M, von Pawel J, Zatloukal P et al (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as fi rst-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27:1227-1234
18. Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434 (Pubitemid 36910021)
19. Yang JC (2004) Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res 10:6367S-6370S (Pubitemid 39287493)
20. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70 (Pubitemid 30046295)
21. McMahon G (2000) VEGF receptor signaling in tumor angiogenesis. Oncologist 5:3-10 (Pubitemid 30225450)
22. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581-611 (Pubitemid 39099316)
23. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011-1027 (Pubitemid 46202320)
24. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401-410 (Pubitemid 37328844)